CNBX Pharmaceuticals Inc.
CNBX
$0.0024
$0.000420.00%
OTC PK
| 02/28/2025 | 11/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 75.82% | -70.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 75.82% | -29.90% | |||
| Operating Income | -75.82% | 29.90% | |||
| Income Before Tax | -102.91% | 43.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -102.91% | 43.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -102.91% | 43.23% | |||
| EBIT | -75.82% | 29.90% | |||
| EBITDA | -148.40% | 64.19% | |||
| EPS Basic | -100.00% | 42.11% | |||
| Normalized Basic EPS | -100.00% | 41.67% | |||
| EPS Diluted | -100.00% | 42.11% | |||
| Normalized Diluted EPS | -100.00% | 41.67% | |||
| Average Basic Shares Outstanding | 3.17% | 0.04% | |||
| Average Diluted Shares Outstanding | 3.17% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||